Download OS for patients with HCL achieving CR with one

Treatment of hairy cell leukemia with 2chlorodeoxyadenosine (2-CdA): long-term follow-up of the
Northwestern University experience
by Punit Chadha, Alfred W. Rademaker, Prateek Mendiratta, Benjamin Kim, Darren
M. Evanchuk, David Hakimian, LoAnn C. Peterson, and Martin S. Tallman
Blood
Volume 106(1):241-246
July 1, 2005
©2005 by American Society of Hematology
Diagram of response and relapse to cycle no. 1 and response to cycle no. 2 in patients with HCL
treated with 2-CdA. * One of the 25 patients was treated with rituximab (CR), and one of 25 was
retreated with 2′-DCF (CR). † One (4%) of 23 patients' responses ...
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
PFS for all 86 patients with HCL. Dotted lines represent 95% confidence limits.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
PFS for previously treated and previously untreated patients with HCL. Tx indicates treated.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
PFS for patients with HCL achieving CR with one cycle of 2-CdA.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
OS for all 86 patients with HCL. Dotted lines represent 95% confidence limits.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
OS for previously treated and previously untreated patients with HCL. Tx indicates treated.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
OS for relapsed patients with HCL. Dotted lines represent 95% confidence limits.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology
OS for patients with HCL achieving CR with one cycle of 2-CdA.
Punit Chadha et al. Blood 2005;106:241-246
©2005 by American Society of Hematology